Morepen Laboratories Limited
General Updates
Morepen Laboratories Limited has informed the Exchange about the name change of its wholly owned subsidiary company from 'Morepen Labs - FZCO' to 'Morepen Labs FZE' effective from 20th July 2026.
26
total announcements
MOREPENLAB.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹6,657 Cr
P/E (TTM)
47.5
EPS (TTM)
₹2.56
52W Low
₹33.05
52W High
₹150.70
Dividend Yield
0.16%
Beta
0.91
Price / Book
5.5
Debt / Equity
16.7
Revenue (TTM)
₹1,951 Cr
Gross Margin
37.10%
Operating Margin
13.01%
Morepen Laboratories Limited
Morepen Laboratories Limited has informed the Exchange about the name change of its wholly owned subsidiary company from 'Morepen Labs - FZCO' to 'Morepen Labs FZE' effective from 20th July 2026.
Morepen Laboratories Limited
Morepen Laboratories Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.
Morepen Laboratories Limited
Morepen Laboratories Limited has informed the Exchange regarding resignation of Mr. Bhola Prasad as General Manager Process Engineering & Technology Transfer, a functional head, being a Senior Management Personnel of the company w.e.f. July 06, 2026.
Morepen Laboratories Limited
Morepen Laboratories Limited has informed the Exchange regarding a press release dated July 01, 2026, titled Morepen starts commercial supplies under its ₹ 825 Crore CDMO mandate. The company has completed the first commercial dispatch valued at approximately ₹50 crore during Q1FY2026-27.
Morepen Laboratories Limited
Morepen Laboratories Limited has informed the Exchange about the elevation and change in designation of Mr. Sanjay Suri from Whole-time Director to Managing Director with effect from 1st July 2026, for the balance tenure of his existing term, i.e., up-to 12th August 2028.
Morepen Laboratories Limited
Morepen Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, for the purpose of considering and approving unaudited consolidated and standalone financial results for the quarter ended on 30th June 2026.